C
Contineum Therapeutics
Creating a portfolio of first-in-class small molecules in neuro-regeneration
About Contineum Therapeutics
Pipeline Therapeutics is a biotechnology company focused on developing next-generation neuro-regenerative therapies. Located near the University of California, San Diego, the company operates in the biopharmaceutical sector, targeting neurological disorders such as hearing loss, multiple sclerosis (MS), and other synaptopathies and demyelinated diseases. Pipeline Therapeutics serves patients and healthcare providers by advancing first-in-class therapeutics aimed at synaptogenesis (the formation of synapses), remyelination (the repair of myelin sheaths around nerves), and axonal repair (restoring function in damaged axons). The business model revolves around research and development (R&D) of small molecules and biologics, which are then licensed or sold to larger pharmaceutical companies or brought to market through strategic partnerships. Revenue is generated through licensing agreements, milestone payments, and royalties from commercialized products. The company is led by Carmine Stengone, President and CEO, and Daniel Lorrain, PhD, Chief Scientific Officer, both of whom bring extensive experience in biotech and pharmaceutical development.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Dec 2025 | $90M | — | Undisclosed | ↗ |
| IPOOther financing | Apr 2024 | $110M | $110M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Contineum Therapeutics is 1.1K monthly website visits, up 292.9% over the last three months. Contineum Therapeutics's team grew 3.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Contineum Therapeutics in the San Diego ecosystem
The Contineum Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Sectoral Asset Management
Versant Ventures
Brace Pharma
Hadean Ventures- RCRBV Capital
Series B and later6 investors entered at this stage
Franklin Templeton Investments
Perceptive Advisors
Casdin Capital
Samsara BioCapital
Suvretta Capital Management
Red Tree Venture Capital
Other known investors1 additional known investor
Scripps Translational Science Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Contineum Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Contineum Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










